Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCEPT intensive care platform trial
2024-516208-41-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 8
01
Overview
Phase 4 trial of tinzaparin, nadroparin, enoxaparin, dalteparin and albumin (human) in critical illness (2 arms), sponsored by Rigshospitalet. Primary endpoint: Domain-specific primary outcome. Planned start Jun 2025; status: authorised.
02
Drugs
tinzaparinnadroparinenoxaparindalteparinalbumin (human)
03
Conditions
critical illness
Beyond the preview
Go deeper on 2024-516208-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516208-41-00.